Clinical Research Exam Bank 2026/2027: 70
Practice Questions on IND Applications,
GCP Compliance, Trial Design, Safety
Monitoring & Regulatory Affairs – With
Detailed Explanations for Certification Prep
Description:
Master clinical research with this comprehensive 2026/2027 exam bank featuring 70
multiple-choice questions covering IND applications, FDA 1572, Investigator's Brochure,
ICH GCP guidelines, double-blind designs, crossover trials, adverse event reporting,
DSMB functions, intention-to-treat analysis, pharmacogenomics, decentralized trials, real-
world evidence, and EU CTR 536/2014. Each question includes detailed explanations to
reinforce learning. Perfect for ACRP, SOCRA, CCRA, CCRC certification candidates,
graduate students in clinical research, pharmaceutical professionals, and regulatory affairs
specialists preparing for exams in 2026/2027.
Download now and pass with confidence!
, Clinical Research Exam Questions 2026 – 70 MCQs with Answers
SECTION A: REGULATORY FRAMEWORKS AND SUBMISSIONS
1. Which regulatory submission is required when seeking permission to conduct the first
human research study with an investigational product and must be updated on an annual
basis?
A. Investigational Device Exemption (IDE)
B. New Drug Application (NDA)
C. Investigator's Brochure (IB)
D. Investigational New Drug Application (IND)
Answer: D
Explanation: The Investigational New Drug Application (IND) is the regulatory submission
required by the FDA before a sponsor can initiate clinical trials in human subjects. It contains
comprehensive background information, preclinical data, and scientific rationale for the
proposed research. The IND must be updated annually to provide the regulatory authority with
ongoing safety information and study progress reports throughout the clinical development
program.
2. The Investigator's Statement (Form FDA 1572) represents:
A. A commitment by the investigator to conduct the study according to Good Clinical Practice
guidelines
B. A summary of all preclinical data related to the investigational product
C. An application for marketing authorization of a new drug
D. A contract between the sponsor and the clinical site
Answer: A
Explanation: Form FDA 1572 is the investigator's statement that serves as a formal commitment
from the principal investigator to conduct the clinical trial in compliance with all regulatory
,requirements, Good Clinical Practice (GCP) standards, and the approved protocol. This
document is executed by sponsors intending to obtain marketing approval for investigational
products and is used both domestically and internationally.
3. What document contains comprehensive clinical and non-clinical data on an
investigational product and is provided to investigators prior to regulatory approval?
A. Protocol Synopsis
B. Investigator's Brochure (IB)
C. Case Report Form (CRF)
D. Informed Consent Document
Answer: B
Explanation: The Investigator's Brochure (IB) is a comprehensive document that collates all
relevant clinical and non-clinical information about the investigational product. It includes
pharmacological data, toxicological findings, pharmacokinetic properties, and any available
clinical experience. The IB is provided to investigators to ensure they have adequate information
to understand the potential risks and benefits associated with the study drug before initiating the
clinical trial.
4. Which of the following represents a standard for designing, conducting, and reporting
clinical trials to ensure data accuracy and protect patient rights and confidentiality?
A. HIPAA Privacy Rule
B. Good Clinical Practice (GCP)
C. Declaration of Helsinki
D. Common Rule
Answer: B
Explanation: Good Clinical Practice (GCP) is an international ethical and scientific quality
standard for designing, conducting, recording, and reporting clinical trials. GCP ensures that the
rights, integrity, and confidentiality of trial subjects are protected and that clinical trial data are
, credible and accurate. Adherence to GCP provides public assurance that the rights and well-
being of trial participants are safeguarded and that the data generated are reliable.
5. According to ICH GCP requirements, what must be evaluated before accepting a clinical
trial protocol?
A. The sponsor's financial stability
B. The principal investigator's publication history
C. The potential to recruit an adequate number of patients, sufficient time to conduct the trial,
and appropriate staff and facilities
D. The commercial potential of the investigational product
Answer: C
Explanation: ICH GCP guidelines stipulate that before accepting a clinical trial protocol, the
research site must demonstrate adequate resources to successfully conduct the study. These
resources include the potential to recruit the required number of eligible patients within the
specified timeframe, sufficient time and personnel to conduct the trial according to the protocol,
and appropriate facilities and equipment to ensure participant safety and data integrity.
SECTION B: CLINICAL TRIAL DESIGN METHODOLOGIES
6. In a clinical trial design where only the patient is unaware of which treatment they are
receiving, but the monitoring team and investigators know, this is referred to as:
A. Open-label study
B. Double-blind study
C. Single-blind study
D. Triple-blind study
Answer: C
Explanation: In a single-blind study design, one party remains unaware of the treatment
assignment, typically the patient. The investigator and monitoring team are aware of which
Practice Questions on IND Applications,
GCP Compliance, Trial Design, Safety
Monitoring & Regulatory Affairs – With
Detailed Explanations for Certification Prep
Description:
Master clinical research with this comprehensive 2026/2027 exam bank featuring 70
multiple-choice questions covering IND applications, FDA 1572, Investigator's Brochure,
ICH GCP guidelines, double-blind designs, crossover trials, adverse event reporting,
DSMB functions, intention-to-treat analysis, pharmacogenomics, decentralized trials, real-
world evidence, and EU CTR 536/2014. Each question includes detailed explanations to
reinforce learning. Perfect for ACRP, SOCRA, CCRA, CCRC certification candidates,
graduate students in clinical research, pharmaceutical professionals, and regulatory affairs
specialists preparing for exams in 2026/2027.
Download now and pass with confidence!
, Clinical Research Exam Questions 2026 – 70 MCQs with Answers
SECTION A: REGULATORY FRAMEWORKS AND SUBMISSIONS
1. Which regulatory submission is required when seeking permission to conduct the first
human research study with an investigational product and must be updated on an annual
basis?
A. Investigational Device Exemption (IDE)
B. New Drug Application (NDA)
C. Investigator's Brochure (IB)
D. Investigational New Drug Application (IND)
Answer: D
Explanation: The Investigational New Drug Application (IND) is the regulatory submission
required by the FDA before a sponsor can initiate clinical trials in human subjects. It contains
comprehensive background information, preclinical data, and scientific rationale for the
proposed research. The IND must be updated annually to provide the regulatory authority with
ongoing safety information and study progress reports throughout the clinical development
program.
2. The Investigator's Statement (Form FDA 1572) represents:
A. A commitment by the investigator to conduct the study according to Good Clinical Practice
guidelines
B. A summary of all preclinical data related to the investigational product
C. An application for marketing authorization of a new drug
D. A contract between the sponsor and the clinical site
Answer: A
Explanation: Form FDA 1572 is the investigator's statement that serves as a formal commitment
from the principal investigator to conduct the clinical trial in compliance with all regulatory
,requirements, Good Clinical Practice (GCP) standards, and the approved protocol. This
document is executed by sponsors intending to obtain marketing approval for investigational
products and is used both domestically and internationally.
3. What document contains comprehensive clinical and non-clinical data on an
investigational product and is provided to investigators prior to regulatory approval?
A. Protocol Synopsis
B. Investigator's Brochure (IB)
C. Case Report Form (CRF)
D. Informed Consent Document
Answer: B
Explanation: The Investigator's Brochure (IB) is a comprehensive document that collates all
relevant clinical and non-clinical information about the investigational product. It includes
pharmacological data, toxicological findings, pharmacokinetic properties, and any available
clinical experience. The IB is provided to investigators to ensure they have adequate information
to understand the potential risks and benefits associated with the study drug before initiating the
clinical trial.
4. Which of the following represents a standard for designing, conducting, and reporting
clinical trials to ensure data accuracy and protect patient rights and confidentiality?
A. HIPAA Privacy Rule
B. Good Clinical Practice (GCP)
C. Declaration of Helsinki
D. Common Rule
Answer: B
Explanation: Good Clinical Practice (GCP) is an international ethical and scientific quality
standard for designing, conducting, recording, and reporting clinical trials. GCP ensures that the
rights, integrity, and confidentiality of trial subjects are protected and that clinical trial data are
, credible and accurate. Adherence to GCP provides public assurance that the rights and well-
being of trial participants are safeguarded and that the data generated are reliable.
5. According to ICH GCP requirements, what must be evaluated before accepting a clinical
trial protocol?
A. The sponsor's financial stability
B. The principal investigator's publication history
C. The potential to recruit an adequate number of patients, sufficient time to conduct the trial,
and appropriate staff and facilities
D. The commercial potential of the investigational product
Answer: C
Explanation: ICH GCP guidelines stipulate that before accepting a clinical trial protocol, the
research site must demonstrate adequate resources to successfully conduct the study. These
resources include the potential to recruit the required number of eligible patients within the
specified timeframe, sufficient time and personnel to conduct the trial according to the protocol,
and appropriate facilities and equipment to ensure participant safety and data integrity.
SECTION B: CLINICAL TRIAL DESIGN METHODOLOGIES
6. In a clinical trial design where only the patient is unaware of which treatment they are
receiving, but the monitoring team and investigators know, this is referred to as:
A. Open-label study
B. Double-blind study
C. Single-blind study
D. Triple-blind study
Answer: C
Explanation: In a single-blind study design, one party remains unaware of the treatment
assignment, typically the patient. The investigator and monitoring team are aware of which
